GleamWall
中文EN

ARGX ARGENX SE IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1697862 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY89.9%
TTM net income YoY55.1%
TTM EPS YoY53.1%
Revenue 3-yr CAGR118.0%
Net income 3-yr CAGR—

Margins

Gross margin89.1%
Operating margin25.4%
Net margin31.1%
FCF margin16.4%
EBITDA margin—

Returns

ROE20.2%
ROA17.4%
ROIC (approx.)26.9%
Asset turnover0.56x

Leverage & solvency

Liabilities / assets15.7%
Debt / equity0.00x
Current ratio5.23x
Interest coverage258.16x

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio8.2%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.15B$2.19B
Cost of revenue$450.67M$227.29M
Gross profit$3.70B$1.96B
R&D expense$1.36B$983.42M
SG&A expense$1.37B$1.06B
Operating income$1.05B-$21.65M
Interest expense$4.08M$2.46M
Pretax income$1.28B$85.18M
Income tax-$13.43M-$747.86M
Net income$1.29B$833.04M
EPS (basic)21.0813.92
EPS (diluted)19.5712.78
Weighted avg. shares (diluted)66.03M65.18M
Balance sheet
Cash & equivalents$3.49B$1.50B
Receivables$1.65B$904.47M
Inventory$473.53M$407.23M
Current assets$6.90B$4.88B
PP&E, netmay include right-of-use assets (IFRS)$48.25M$43.52M
Intangibles$272.10M$181.44M
Total assets$8.68B$6.20B
Current liabilities$1.32B$669.92M
Total liabilities$1.36B$704.24M
Shareholders' equity$7.32B$5.50B
Shares outstanding61.88M60.76M
Cash flow statement
Operating cash flow$685.19M-$82.75M
Capital expenditure$6.17M$1.80M
Free cash flow$679.03M-$84.55M
Investing cash flow$984.00M-$717.59M
Financing cash flow$233.01M$279.76M
Stock-based compensation$248.08M$235.18M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.